Not All ‘Jolie Genes’ Are Created Equal: New Study Reveals Nuances in BRCA Mutation Impact on Breast Cancer
A landmark international study published in Annals of Oncology reveals that not all mutations in the BRCA1 and BRCA2 genes – often referred to as the “Jolie genes” – carry the same risk for breast cancer patients. The research demonstrates that some genetic defects are linked to a more aggressive prognosis and reduced survival rates, while others appear to have a less significant impact on disease progression.
The findings are poised to revolutionize how clinicians assess risk for individuals carrying BRCA mutations, potentially leading to more personalized and effective treatment strategies.
For the first time, researchers have demonstrated a clear correlation between the type of BRCA mutation and patient outcomes, specifically in women under 40 diagnosed with invasive breast cancer. The collaborative effort, known as the BRCA BCY Collaboration, involved 109 centers across 33 countries and analyzed data from 3,294 patients diagnosed between 2000 and 2020.
“This retrospective investigation allows us to evaluate a patient’s real risk with greater precision,” explained a lead researcher from the Irccs Policlinico San Martino Hospital. “We can now consider intensifying treatments and surveillance for women with ‘bad’ genetic mutations, while potentially adopting a more measured approach for those with less aggressive variants.”
BRCA1 and BRCA2 genes are crucial for DNA repair. When these genes are mutated, the body’s ability to fix DNA damage is compromised, increasing the likelihood of tumor development. Inherited mutations in these genes can elevate the lifetime risk of breast cancer by up to 80% and ovarian cancer by up to 40%. While approximately one in ten breast cancers are linked to defects in these genes, the clinical implications of the specific mutation have remained largely unknown – until now.
The study’s key innovation lies in its detailed analysis of thousands of possible BRCA mutations, assessing the impact of individual variants on the survival rates of young patients with invasive cancer. Researchers previously understood that BRCA1 mutations were more commonly found in triple-negative breast cancers, while BRCA2 mutations were more prevalent in estrogen receptor-positive tumors. However, this new data delves deeper, evaluating the influence of specific mutation types.
“We’ve observed that mutations which ‘truncate’ BRCA1 and BRCA2 – effectively shortening and destabilizing the protein – significantly impair functionality and lead to a worsening of survival,” stated a professor at the University of Modena and Reggio Emilia. “Conversely, mutations that alter only a single DNA letter, changing just one amino acid in the final protein, appear to be associated with longer life expectancy. Ultimately, the consequence of the mutation on the protein’s functionality appears to be the most critical factor.”
Researchers believe that identifying these associations between mutation type and cancer characteristics – including aggressiveness – will be instrumental in optimizing treatment strategies. The presence of variants linked to poorer prognoses could justify more frequent surveillance or the implementation of more intensive therapies, tailored to the potential impact of the mutation on survival expectancy.
“Identifying these associations can help optimize treatment strategies,” researchers concluded. “This is a significant step towards personalized medicine in breast cancer care.”
